The evolving field of hormone-sensitive prostate cancer

Poster Session 74

Monday 18 March
14:00 - 15:30

Location: Green Area, Room 4

Chairs: G.P. Haas, Syracuse (US)
A. Morgans, Chicago (US)
B. Ralla, Berlin (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1033

The role of abiraterone acetate plus prednisone/prednisolone in high- and low-risk metastatic hormone sensitive prostate cancer

By: Hoyle A.P.¹, Ali A.¹, James N.D.², Parker C.C.³, Cooke A.⁴, Attard G.⁵, Chowdhury S.⁶, Cross W.R.⁷, Dearmaley D.P.³, De Bono J.S.³, Gilson C.⁴, Gillessen S.¹, Jones R.J.⁸, Matheson D.⁹, Mason M.D.¹⁰, Ritchie A.W.S.⁴, Russell M.⁸, Douis H.¹¹, Parmer M.K.B.⁴, Sydes M.R.⁴, Clarke N.W.¹

¹The Christie GenitoUrinary Research Group, Dept. of Surgery, The Christie Hospital, Manchester, United Kingdom
²Institute of Cancer and Genomic Studies, Dept. of Oncology, Birmingham, United Kingdom
³Academic Urology Unit, Dept. of Medical Oncology, London, United Kingdom
⁴Medical Research Council, Clinical Trials Unit, London, United Kingdom
⁵University College London Cancer Institute, Dept. of Oncology, London, United Kingdom
⁶Guys and St Thomas NHS Foundation trust, Dept. of Medical Oncology, London, United Kingdom
⁷St James University Hospital, Dept. of Urology, Leeds, United Kingdom
⁸Beatson West of Scotland Cancer Centre, Dept. of Medical Oncology, Glasgow, United Kingdom
⁹University of Wolverhampton, Faculty of Education, Health and Wellbeing, Wolverhampton, United Kingdom
¹⁰Cardiff University, Division of Cancer and Genetics, Cardiff, United Kingdom
¹¹University Hospital Birmingham NHS Foundation Trust, Dept. of Radiology, Birmingham, United Kingdom

Aims and objectives of this presentation

1033

Survival in men with de novo metastatic prostate cancer before and after the introduction of chemotherapy for advanced prostate cancer: A nationwide, population-based study

By: Westerberg M.¹, Franck Lissbrant I.², Damber J.E.², Robinson D.³, Garmo H.⁴, Stattn P.⁴

¹Uppsala University, Dept. of Mathematics, Uppsala, Sweden
²Institute of Clinical Sciences, Sahlgrenska Academy at University of Göteborg, Dept. of Oncology, Gothenburg, Sweden
³Ryrov Hospital, Dept. of Urology, Jönköping, Sweden
⁴Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden
Aims and objectives of this presentation
1034

*Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)*


1Malteser Hospital Bonn, Dept. of Urology, Bonn, Germany, 2Praxis für Urologie Pankow, Dept. of Urology, Berlin, Germany, 3Praxisgemeinschaft für Urologie, Dept. of Urology, Borken, Germany, 4Urologicum Duisburg, Dept. of Urology, Duisburg, Germany, 5Urologikum Hamburg, Dept. of Urology, Hamburg, Germany, 6Saarland University Medical Center, Dept. of Urology, Homburg, Germany, 7Praxis für Urologie, Dept. of Urology, Kempen, Germany, 8Zentrum für Onkologie und Urologie Rostock, Dept. of Urology, Rostock, Germany, 9PANDAMED Wuppertal, Dept. of Urology, Wuppertal, Germany, 10DGU Wuppertal, Dept. of Urology, Wuppertal, Germany, 11Urologische Gemeinschaftspraxis, Dept. of Urology, Zwickau, Germany, 12Studienpraxis Urologie, Dept. of Urology, Nürtingen, Germany, 13Urologische Praxisgemeinschaft, Dept. of Urology, Wolfsburg, Germany, 14Urologische Partnerschaft Köln, Dept. of Urology, Cologne, Germany

Aims and objectives of this presentation
1035

1036

Inpatient morbidity and cost of cytoreductive radical prostatectomy in the United States

By: Arora S.1, Sood A.1, Dalela D.1, Keeley J.1, Rakic N.2, Prokopiv U.2, Fotouhi A.2, Peabody J.O.1, Mani M.1, Abdollah F.1

1Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America, 2Wayne State University School of Medicine, Medical School, Detroit, United States of America

Aims and objectives of this presentation
1036

1037

Neoadjuvant apalutamide (arn-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) – initial results of a phase II trial

By: Aslim E.J.1, Yang X.1, Ngo N-T.2, Khor L.Y.2, Chen K.1, Chong T.W.1, Yuen J.S.P.1, Tay K.J.1, Ho H.S.S.1, Lee L.S.1

1Singapore General Hospital, Dept. of Urology, Singapore, Singapore, 2Singapore General Hospital, Dept. of Pathology, Singapore, Singapore

Aims and objectives of this presentation
1037
Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis

By: Feyerabend S.¹, Saad F.², Ito T.³, Diels J.⁴, Van Sanden S.⁴, De Porre P.⁵, Roiz J.⁶, Abogunrin S.⁷, Koufopoulou M.⁷, Fizazi K.⁸

¹Studienpraxis Urologie, Dept. of Urologic, Oncology, Nürtingen, Germany, ²Centre Hospitalier de l’Université de Montréal/CRCHUM, Dept. of Urologic, Oncology, Montréal, Canada, ³Janssen, Dept. of Health Economics & Market Access EMEA, High Wycombe, United Kingdom, ⁴Janssen, Dept. of Health Economics & Market Access EMEA, Beerse, Belgium, ⁵Janssen, Dept. of Research & Development, Clinical Oncology, Beerse, Belgium, ⁶Evidera, Dept. of Modelling and Simulation, London, United Kingdom, ⁷Evidera, Dept. of Meta Research, London, United Kingdom, ⁸University of Paris Sud, Gustave Roussy, Villejuif, France

Aims and objectives of this presentation

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

By: Peltomaa A.I.P.¹, Talala K.², Taari K.³, Tammela T.L.J.⁴, Auvinen A.⁵, Murtola T.¹

¹University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, ²Finnish Cancer Registry, Dept. of Cancer Statistics, Helsinki, Finland, ³Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁴Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁵University of Tampere, Faculty of Social Sciences, Tampere, Finland

Aims and objectives of this presentation

Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin-releasing hormone (GnRH) agonist for prostate cancer: Final analysis of the EQUINOXE study

By: Droupy S.¹, Colson M.², Pello-Leprince-Ringuet N.³, Perrot V.³, Descazeaud A.⁴

¹CHU de Nîmes, Dept. of Urology, Nîmes, France, ²CHU de Marseille, Dept. of Sexology, Marseille, France, ³Ipsen Pharma, Dept. of Urology, Boulogne-Billancourt, France, ⁴CHU de Limoges, Dept. of Urology, Limoges, France

Aims and objectives of this presentation

Initial patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial

By: Yang X.Y.¹, Aslim E.J.², Chen K.³, Chong T.W.⁴, Yuen J.S.P.⁵, Tay K.J.⁶, Ho H.S.S.⁷

¹Scientific Programme - EAU19 Barcelona
Aims and objectives of this presentation

1043

Identifying the optimal postoperative strategies for clinically node positive patients treated with radical prostatectomy and extended pelvic lymph node dissection: Is androgen deprivation therapy always mandatory?

By: Gandaglia G.¹, Karnes R.J.², Devos G.³, Battaglia A.³, Mulwijk T.³, Soligo M.², Evaraets W.³, Boeri L.², Robesti D.¹, Cannoletta D.¹, Zaffuto E.¹, Scuderi S.¹, Barletta F.¹, Karakiewicz P.I.⁴, Fossati N.¹, Moschini M.², Joniau S.³, Montorsi F.¹, Briganti A.¹

¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology URI, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester (MN), United States of America, ³University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁴University of Montreal Health Center, Montreal, Cancer Prognostics and Health Outcomes Unit, Division of Urology, Montreal, Canada

Aims and objectives of this presentation

1044

15:17 - 15:24

State-of-the-art lecture Contemporary management of hormone sensitive prostate cancer

A. Morgans, Chicago (US)